As of January 22, 2025, Alto Neuroscience (ANRO) has a market cap of $0.12 billion USD. According to our data, Alto Neuroscience is ranked No.7538 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.12 B |
6.86%
|
Dec 31, 2024 | $0.11 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Sage Therapeutics
SAGE
|
$0.43 B |
-0.000 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Axsome Therapeutics
AXSM
|
$4.96 B |
0.000 M
|
USA
|
Intra-Cellular Therapies
ITCI
|
$13.51 B |
-0.000 M
|
USA
|
ACADIA Pharmaceuticals
ACAD
|
$2.96 B |
-0.000 M
|
USA
|
Vanda Pharmaceuticals
VNDA
|
$0.25 B |
-0.000 M
|
USA
|
Neurocrine Biosciences
NBIX
|
$14.86 B |
-0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Jazz Pharmaceuticals
JAZZ
|
$7.31 B |
0.000 M
|
Ireland
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Market Cap | = | ANRO Stock Price | * | ANRO Shares Outstanding |
= | $4.52 | * | 26.97 M | |
= | $0.12 B |